R&D Trends

Ablynx, AbbVie enter global license agreement for inflammatory diseases

Monday, September 23, 2013 01:37 PM

Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies, and AbbVie have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.

More... »

NYSCF an associate member of NYGC

Friday, September 20, 2013 11:07 AM

The New York Stem Cell Foundation (NYSCF) has become an associate member of The New York Genome Center (NYGC), joining NYGC's growing consortium of 16 research and clinical institutions, all working together in new ways to utilize genomic data for better detection, treatment, and prevention of disease.

More... »

H3 Biomedicine, Selvita collaborate

Wednesday, September 18, 2013 01:41 PM

H3 Biomedicine, a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita, a drug discovery company in Eastern Europe, have are collaborating to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets.

More... »

Texas Heart Institute, TAMU receive $3m for biotechnology center

Wednesday, September 18, 2013 11:04 AM

The Texas Heart Institute (THI) and Texas A&M University (TAMU) College of Veterinary Medicine and Biomedical Sciences have received a $3 million grant through the Texas Emerging Technology Fund (TETF) to create the Center for Cell and Organ Biotechnology

More... »

MIT awarded $25m for human computer development

Wednesday, September 18, 2013 10:42 AM

The National Science Foundation (NSF) has awarded $25 million to establish a Center for Brains, Minds and Machines at the Massachusetts Institute of Technology (MIT). The center is one of three new research centers funded this year through NSF's Science and Technology Centers: Integrative Partnerships program.

More... »

NIH scientists pursue new therapies to improve rare disease drug development

Monday, September 16, 2013 08:00 AM

Four new preclinical drug development projects at the NIH will target a form of blindness and diseases characterized by cardiac problems. The projects were selected for their potential to treat specific rare diseases and to help scientists uncover new information that can be shared with other researchers.

More... »

Analysis: Biotechs continue to invest in R&D

Friday, September 13, 2013 01:13 PM

Amid a robust period in the biotech industry, R&D spending continues to rise. According to the third annual study from accounting and consulting firm BDO USA, average R&D expenditure among biotechs increased 8% in 2012, compared to a 4% increase in 2011.

More... »

Genia, Columbia, Harvard awarded DNA sequencing technology grant

Friday, September 13, 2013 01:10 PM

Genia Technologies has announced, as part of a research consortium with Columbia University and Harvard Medical School, it has received a Revolutionary Genome Sequencing Technologies—The $1,000 Genome grant from the National Human Genome Research Institute (NHGRI) of the NIH.  The grant, $5.25 million for three years, will be used in collaboration with investigators at Columbia and Harvard to further develop Genia's nanopore-based DNA sequencing platform that allows for single molecule, electrical, real-time analysis.  

More... »

Advanced Biological Laboratories, Roche Diagnostics collaborate

Wednesday, September 11, 2013 01:45 PM

Advanced Biological Laboratories (ABL) has signed a non-exclusive collaboration agreement with Roche Diagnostics International for Europe, Middle East, Africa (EMEA) and Latin America (LATAM) territories.

More... »

AstraZeneca, Merck enter license agreement for cancer

Wednesday, September 11, 2013 01:43 PM

AstraZeneca and Merck have announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase, MK-1775, currently being evaluated in phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer.

More... »